HiveBio Cohort 1 is Defying the Odds — $1.7M Raised and Counting
- Sep 16
- 2 min read
Updated: Sep 16
In a world where most startups struggle to find early capital, the HiveBio ecosystem is steadily rewriting the narrative.
As of this moment, we’re proud to officially report a 60% success rate in helping our startups raise external funding. Together, HiveBio-backed ventures have collectively raised $1.725M USD while actively participating in our programs. These numbers aren't just abstract milestones — they represent lives changed, research accelerated, and solutions brought closer to the people who need them.
Here are some of the standout stories:
BioLattice — $92.5K
1st Place Winner at Innovation Nest (Start-up World Cup)
Top 10 Finalist at MedTechColor Road Tour
Winner of Top Pitch at BioLabs Advanced Therapeutics Investor Day
Higher Medicine — $200K
Strategic Partnership + Funding from 5 Horizons Capital
Preparing for Phase 1b/2a Human Clinical Trial
Secured strategic IP option with Johns Hopkins
Vasowatch — $120K
Published at CHASE 2025 Conference
Multiple pitch accolades across HLTH, Bio North Texas, MIT Solve, and more
Drs.LINQ — $425K
$25K grant + office space from PA Biotech Center
500-unit verbal purchase commitment pending FDA clearance
Active distribution conversations in Canada and India
Bound Therapeutics — $500K
Finalist: Entrepreneurs Next Star North America Track (potential $400K Global Prize)
Accepted into HKSTP Ideation Program
Multiple international speaking engagements (RNA World, BIOHK25, etc.)
SBIR Fast-Track resubmission to NIH ($2.3M)
Trevarx Biomedical — $390K
Grant from City of Philadelphia
SBIR/STTR Phase II TABA Support Grant ($40K)
Beyond the dollars is the deeper story—one of validation, momentum, and readiness:
QuneUp has secured two binding LOIs from enterprise customers, already eager to deploy its supply chain solution when ready.
Cerespectus is now preparing for in-vivo testing of their proprietary catheter scope in a pig model.
Valfard Therapeutics has demonstrated 100% wound closure in early therapeutic testing, partnered with Melior Discovery on DFU model development, and is currently negotiating a major strategic partnership in Pittsburgh. With mentorship from HiveBio's network, Valfard also finalized its reimbursement strategy for diabetic foot ulcer treatment with guidance from Norris Turner.
BioLattice filed an international patent in July with the U.S. Receiving Office of the Patent Cooperation Treaty, and on the regulatory side, a pre-RFD was submitted to the FDA, which confirmed that CorneaClear qualifies as a medical device and scheduled a pre-submission meeting for November 2025.
From strategic partnerships to competitive wins, from IP licensing to grant resubmissions, the HiveBio community continues to embody what happens when aligned vision, collaborative mentorship, and bold science meet.